Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

GBT

Global Blood Therapeutics (GBT)

Global Blood Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GBT
FechaHoraFuenteTítuloSímboloCompañía
09/02/202310:04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
17/10/202207:34Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:GBTGlobal Blood Therapeutics Inc
06/10/202215:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202215:41Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202215:33Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202215:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202208:00Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:GBTGlobal Blood Therapeutics Inc
15/09/202217:00GlobeNewswire Inc.GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
12/09/202215:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/09/202207:00GlobeNewswire Inc.GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/08/202207:01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
09/08/202207:35TipRanksGlobal Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB SecuritiesNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202206:29Dow Jones NewsGlobal Blood Therapeutics Shares Rise Premarket After Pfizer DealNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202206:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202205:45GlobeNewswire Inc.Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyNASDAQ:GBTGlobal Blood Therapeutics Inc
04/08/202215:05GlobeNewswire Inc.GBT Announces New Employment Inducement GrantsNASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202216:46Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202215:05GlobeNewswire Inc.GBT Announces Participation at the Wedbush PacGrow Healthcare ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/07/202207:00GlobeNewswire Inc.GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
26/07/202202:01GlobeNewswire Inc.MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and OlderNASDAQ:GBTGlobal Blood Therapeutics Inc
14/07/202207:00GlobeNewswire Inc.GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in BrazilNASDAQ:GBTGlobal Blood Therapeutics Inc
13/07/202207:00GlobeNewswire Inc.The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based OrganizationsNASDAQ:GBTGlobal Blood Therapeutics Inc
08/07/202221:10TipRanksRBC Capital Keeps a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/07/202204:08TipRanksWilliam Blair Sticks to Its Buy Rating for Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202211:55TipRanksWedbush Reiterates a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202207:00GlobeNewswire Inc.GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
17/06/202215:05Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GBTGlobal Blood Therapeutics Inc
16/06/202207:00GlobeNewswire Inc.NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202207:00GlobeNewswire Inc.New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202205:45TipRanksWedbush Thinks Global Blood Therapeutics’ Stock is Going to RecoverNASDAQ:GBTGlobal Blood Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GBT

Su Consulta Reciente

Delayed Upgrade Clock